NHS
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
NHS searches for healthcare innovators
January 8, 2015Medical Communications, Sales and Marketing NHS, UK, innovation, programme, sir bruce keogh
NHS England and medical director Sir Bruce Keogh have launched an NHS Innovation Accelerator Programme. The initiative will invite healthcare …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
NHS plans bashed over cancer and heart disease
December 24, 2014Research and Development, Sales and Marketing Cancer, England, NHS, Simon Stevens, funding, heart
Hundreds of healthcare experts have signed an open letter to NHS chief executive Simon Stevens calling for him to scrap …
NICE rejects Takeda Crohn’s disease drug
December 23, 2014Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab
Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …
NHS not au fait with mobile-savvy patients
December 19, 2014Medical Communications, Sales and Marketing NHS, app, digital, health, mobile, smartphones, wearables
The NHS is failing to keep up with its digital generation of patients, a recent study has found. Despite a …
Janssen launches HIV combination pill
December 17, 2014Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost
Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
NICE changes insulin advice in diabetes guidelines
December 12, 2014Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2
NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …
Half of England on prescription drugs
December 11, 2014Sales and Marketing England, HSCIC, NHS, doctors, prescribing, prescriptions
Almost half of the people in England are taking regular prescription medicines according to a new report by the Health …
Private firms account for a third of NHS contracts
December 10, 2014Medical Communications, Sales and Marketing Budget, Cameron, Hunt, NHS, Osborne, autumn, election, privatisation
A large percentage of NHS contracts in England have been awarded to private sector providers since 2013, according to data …
Labour to extend cancer drugs funding if elected
December 10, 2014Research and Development, Sales and Marketing CDF, Cancer, Labour, NHS, NICE, andy burnham, election
Labour has committed to continuing the Cancer Drugs Fund system under the guise of a new £330 million ‘Cancer Treatment …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Government seeks stakeholder consultation over NICE
December 4, 2014Sales and Marketing ABPI, NHS, NICE, UK, emms, freeman, government, ndpb
NICE stakeholders are being asked for their views on its future as part of the government’s ongoing review into the …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
